Table 1 The PMTCT options and interventions for the mother and baby
Treatment (for CD4 count <350 cells/mm3) | Prophylaxis (for CD4 count >350 cells/mm3) | Infant receives | |
|---|---|---|---|
Option A | Triple ARVs starting as soon as diagnosed, continued for life | Antepartum: AZT starting as early as 14 weeks gestation Intrapartum: at onset of labour, single-dose NVP and first dose of AZT/3TC Postpartum: daily AZT/3TC through 7 days postpartum | Daily NVP from birth until 1 week after cessation of all breastfeeding; or, if not breastfeeding or if mother is on treatment, through age 4–6 weeks |
Option B | Triple ARVs starting as soon as diagnosed, continued for life | Triple ARVs starting as early as 14 weeks gestation and continued intrapartum andthrough childbirth if not breastfeeding or until 1 week after cessation of all breastfeeding | Daily NVP or AZT from birththrough age 4–6 weeks regardless of infant feeding method |
Option B+ | Triple ARVs starting as soon as diagnosed, continued for life | Triple ARVs starting as soon as diagnosed, continued for life | Daily NVP or AZT from birth through age 4–6 weeks regardless of infant feeding method |